Dyax Corp. Licenses Antibody Phage Display Libraries to Cambridge Antibody Technology

06-Aug-2007

Dyax Corp. announced that they have licensed their antibody phage display libraries to Cambridge Antibody Technology (CAT), a wholly-owned subsidiary of AstraZeneca, for the discovery of therapeutic antibodies. CAT will receive sublicenses to relevant third-party antibody phage display patents that may be used with Dyax's technology. The agreement allows CAT the ability to commercialize up to 20 royalty bearing therapeutic antibody products. Financial terms of the agreement are not disclosed.

Henry E. Blair, Chairman, President and Chief Executive Officer of Dyax, commented, "We are very pleased to have entered into an agreement with CAT, a company that has demonstrated the capability to discover, develop and commercialize therapeutic antibodies. This collaboration helps further validate Dyax's antibody phage display technology platform. We are continuing to create value in our Licensing and Funded Research Program, which has more than 70 collaborators and licensees, and has generated 13 product candidates that are currently in clinical trials."

Other news from the department business & finance

More news from our other portals

So close that even
molecules turn red...

See the theme worlds for related content

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous

View topic world
Topic world Antibodies

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous